Korro Bio (KRRO) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nkarta (NKTX) has outperformed Korro Bio (KRRO) over the past year, gaining 6.2% versus a loss of 76.9%. Over five years, NKTX leads with a -87.9% price change compared with -97.0% for KRRO. Nkarta is the larger company by market cap ($159.0 million vs $155.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | NKTX |
|---|---|---|
| Share price | $10.58 | $2.22 |
| Market cap | $155.80M | $159.01M |
| 1-day change | +0.86% | -2.20% |
| YTD return | +32.08% | +20.00% |
| 1-year return | -76.90% | +6.22% |
| 5-year return | -97.02% | -87.90% |
| EPS (TTM) | $-9.88 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.89 | $3.72 |
| 52-week low | $5.20 | $1.70 |
| Distance from 52-week high | -81.07% | -40.32% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +90.93% | +387.84% |
| Average volume | 148.80K | 617.86K |
| Shares outstanding | 14.73M | 71.62M |
| Employees | 57 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed KRRO by 83.1 percentage points over the past year.
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
KRRO vs NKTX FAQ
Which is bigger, Korro Bio or Nkarta?
Nkarta (NKTX) is larger, with a market capitalization of $159.01M compared with $155.80M for Korro Bio (KRRO).
Which stock has performed better over the past year, KRRO or NKTX?
NKTX returned +6.22% over the past 12 months, compared with -76.90% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Korro Bio and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.